MedTrace Logo

Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases

NCT05859997 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-11-20

No results posted yet for this study

Summary

This is an investigator initiated trial to assess the efficacy and safety of BRL-301 in the relapse or refractory autoimmune diseases of China.

Conditions

  • Systemic Lupus Erythematosus (SLE)
  • Sjogren's Syndrome
  • Systemic Sclerosis
  • Inflammatory Myopathy
  • ANCA Associated Systemic Vasculitis
  • Antiphospholipid Syndrome

Interventions

BIOLOGICAL

BRL-301

Single dose of Allogeneic Anti-CD19 CAR T cells will be infused

Sponsors & Collaborators

  • Shanghai Changzheng Hospital

    collaborator OTHER

  • Bioray Laboratories

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-17
Primary Completion
2024-05-27
Completion
2025-05-27

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05859997 on ClinicalTrials.gov